|
Home |
| Browse | |
|
|
Communities & Collections |
|
|
Issue Date |
|
|
Author |
|
|
Title |
|
|
Subject |
| Sign on to: | |
|
|
Receive email updates |
|
|
My APO authorized users |
|
|
Edit Profile |
|
|
|
|
|
About DSpace |
ANSTO Publications Online >
Journal Publications >
Journal Articles >
Please use this identifier to cite or link to this item:
http://apo.ansto.gov.au/dspace/handle/10238/2848
|
| Title: | Technology evaluation: huN901-DM1 (ImmunoGen). |
| Authors: | Smith, SV |
| Keywords: | Evaluation Neoplasms Lungs Commercialization Drugs Antibodies |
| Issue Date: | 25-Jul-2005 |
| Publisher: | Thomson Reuters |
| Citation: | Smith, S. V. (2005). Technology evaluation: huN901-DM1 (ImmunoGen). Current Opinion in Molecular Therapeutics, 7(4), 394-402. |
| Abstract: | ImmunoGen is developing huN901-DMI, a compound comprised of a CD56-targeted humanized N901 antibody conjugated to the company's proprietary cytotoxic agent. DM1, using its tumor-activated prodrug technology, for the potential treatment of cancers that express CD56, in particular, small-cell lung cancer. © 2005, Thomson Reuters |
| URI: | http://www.biomedcentral.com/content/pdf/cd-614041.pdf http://apo.ansto.gov.au/dspace/handle/10238/2848 |
| ISSN: | 1464-8431 |
| Appears in Collections: | Journal Articles |
Files in This Item: There are no files associated with this item. |
Items in APO are protected by copyright, with all rights reserved, unless otherwise indicated.
|
DSpace Software Copyright © 2002-2010 Duraspace - Feedback |